Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma
Jennifer L. Crombie(Dana-Farber Cancer Institute), Anthony Letai(Dana-Farber Cancer Institute), Amanda L. Christie(Dana-Farber Cancer Institute), Shruti Bhatt(Dana-Farber Cancer Institute), Chen Lossos, Matthew S. Davids(Dana-Farber Cancer Institute), Jing Deng(Guangdong Provincial Center for Disease Control and Prevention), Kristopher A. Sarosiek(Harvard University), Cameron Fraser(Harvard University), David M. Weinstock(Broad Institute)
Cited by 2
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752